What is the prevalence of Retinoblastoma?

Retinoblastoma is a rare, life-threatening pediatric eye cancer with an estimated global incidence of approximately 1 in 15,000 to 1 in 20,000 live births. While it is considered a rare disease, it is the most common primary intraocular malignancy in childhood, typically manifesting before the age of five.

What is the global incidence and prevalence of Retinoblastoma?

The incidence of Retinoblastoma is relatively consistent worldwide, affecting approximately 8,000 to 9,000 children annually. Because Retinoblastoma is a condition that generally presents in early childhood and is successfully treated in many developed nations, the prevalence—the total number of people living with the condition at any given time—is lower than the incidence. In high-income countries, survival rates often exceed 95%, whereas in low-income settings, mortality rates remain significantly higher due to delayed diagnosis and limited access to specialized ocular oncology care.

Does Retinoblastoma affect specific demographics differently?

Retinoblastoma shows no significant predilection for sex; boys and girls are affected with equal frequency. Regarding ethnicity and geography, the incidence rate is remarkably stable across different populations, suggesting that environmental factors play a lesser role compared to genetic predisposition. However, the outcomes of Retinoblastoma vary drastically by geographic region, often correlated with the availability of early screening programs and advanced treatments like systemic chemotherapy, intra-arterial chemotherapy, and focal laser therapy.

At what age does Retinoblastoma typically occur?

Retinoblastoma is almost exclusively a disease of early childhood. The median age at diagnosis is typically between 18 and 24 months. Cases diagnosed after the age of five are exceptionally rare. The disease is categorized into two main forms:

• Heritable Retinoblastoma: Often bilateral (affecting both eyes) and diagnosed earlier, typically within the first year of life.


• Non-heritable Retinoblastoma: Usually unilateral (affecting one eye) and diagnosed slightly later, often between ages two and three.

What are the challenges in tracking Retinoblastoma data?

While Retinoblastoma is a reportable condition in many national cancer registries, accurate prevalence data can be difficult to capture globally. Underdiagnosis remains a major issue in resource-limited settings where children may pass away from metastatic disease before a formal diagnosis is recorded. Furthermore, as survivors of Retinoblastoma age, they require lifelong monitoring for secondary malignancies, which complicates long-term epidemiological tracking. Within the DiseaseMaps.org community, 8 people have shared their experiences, providing a crucial real-world perspective on the long-term journey of living with or surviving Retinoblastoma.

Next steps

• Consult a pediatric ophthalmologist or ocular oncologist immediately if you notice a white glow in a child's pupil (leukocoria) or persistent strabismus.


• If there is a family history of Retinoblastoma, seek genetic counseling to discuss pre-symptomatic screening for newborns.


• Join specialized support networks, such as the community at DiseaseMaps.org, to connect with others who understand the unique challenges of this rare eye cancer.


• Participate in clinical registries if offered by your medical team to help researchers improve future treatment protocols.

Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Retinoblastoma (ORPHA: 793).


• NIH Genetic and Rare Diseases Information Center (GARD): Retinoblastoma.


• American Academy of Ophthalmology (AAO): Clinical information on intraocular pediatric malignancies.


• OMIM (Online Mendelian Inheritance in Man): Entry #180200 (Retinoblastoma).